Molecular engineering of the antitumor immune response.
Pardoll
D M
DM
Dept. of Oncology, Medicine and Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Golumbek
P
P
Levitsky
H
H
Jaffee
L
L
D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology*; D015316:Genetic Therapy; D007155:Immunologic Factors / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D007167:Immunotherapy; D008222:Lymphokines / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000628:therapy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000378:metabolism / Q000637:transplantation
D000951:Antigens, Neoplasm; D007155:Immunologic Factors; D008222:Lymphokines; D011994:Recombinant Proteins